<DOC>
	<DOCNO>NCT00062491</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Karenitecin ( BNP1350 ) treatment Malignant Melanoma .</brief_summary>
	<brief_title>Study Karenitecin ( BNP1350 ) Treat Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Confirmed diagnosis malignant melanoma Measurable disease Granulocytes ≥1,500/µl , Platelets ≥100,000/µl , Creatinine ≤ULN , Bilirubin ≤1.5 mg/dl , AST ≤2.5 x ULN No prior treatment camptothecin drug . ≥ 21 day since completion prior chemotherapy , ≥6 week since prior MitomycinC ECOG Performance Status 01 Negative pregnancy test female patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>